Compare LCTX & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | KLTR |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 238.4M |
| IPO Year | N/A | 2021 |
| Metric | LCTX | KLTR |
|---|---|---|
| Price | $1.65 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $4.25 | $3.50 |
| AVG Volume (30 Days) | ★ 1.3M | 344.4K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,816,000.00 | ★ $180,921,000.00 |
| Revenue This Year | $6.32 | $3.10 |
| Revenue Next Year | $124.49 | $1.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | 1.88 |
| 52 Week Low | $0.37 | $1.36 |
| 52 Week High | $2.09 | $2.82 |
| Indicator | LCTX | KLTR |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 52.30 |
| Support Level | $1.63 | $1.64 |
| Resistance Level | $1.77 | $1.73 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 46.15 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.